JP2008505644A - 食道癌、結腸癌、頭頸部癌、およびメラノーマにおけるマーカーの同定 - Google Patents
食道癌、結腸癌、頭頸部癌、およびメラノーマにおけるマーカーの同定 Download PDFInfo
- Publication number
- JP2008505644A JP2008505644A JP2007520520A JP2007520520A JP2008505644A JP 2008505644 A JP2008505644 A JP 2008505644A JP 2007520520 A JP2007520520 A JP 2007520520A JP 2007520520 A JP2007520520 A JP 2007520520A JP 2008505644 A JP2008505644 A JP 2008505644A
- Authority
- JP
- Japan
- Prior art keywords
- mrna species
- specific
- excess
- lymph nodes
- assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 24
- 208000000461 Esophageal Neoplasms Diseases 0.000 title claims abstract description 19
- 206010030155 Oesophageal carcinoma Diseases 0.000 title claims abstract description 19
- 201000004101 esophageal cancer Diseases 0.000 title claims abstract description 19
- 208000029742 colonic neoplasm Diseases 0.000 title claims abstract description 18
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 17
- 201000010536 head and neck cancer Diseases 0.000 title description 8
- 208000014829 head and neck neoplasm Diseases 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 187
- 230000014509 gene expression Effects 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims abstract description 15
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims abstract description 15
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract description 15
- 210000001165 lymph node Anatomy 0.000 claims description 118
- 108020004999 messenger RNA Proteins 0.000 claims description 114
- 150000007523 nucleic acids Chemical class 0.000 claims description 105
- 108020004707 nucleic acids Proteins 0.000 claims description 91
- 102000039446 nucleic acids Human genes 0.000 claims description 91
- 239000000523 sample Substances 0.000 claims description 87
- 210000004027 cell Anatomy 0.000 claims description 83
- 238000003556 assay Methods 0.000 claims description 80
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 65
- 230000003321 amplification Effects 0.000 claims description 60
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 59
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 239000003550 marker Substances 0.000 claims description 49
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 42
- 239000013614 RNA sample Substances 0.000 claims description 40
- 102100034577 Desmoglein-3 Human genes 0.000 claims description 38
- 101000924311 Homo sapiens Desmoglein-3 Proteins 0.000 claims description 38
- 101000641959 Homo sapiens Villin-1 Proteins 0.000 claims description 30
- 230000001394 metastastic effect Effects 0.000 claims description 27
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 27
- 238000001514 detection method Methods 0.000 claims description 23
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 22
- 239000005022 packaging material Substances 0.000 claims description 21
- 102000043299 Parathyroid hormone-related Human genes 0.000 claims description 19
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 claims description 17
- 102100033419 Villin-1 Human genes 0.000 claims description 16
- 238000003757 reverse transcription PCR Methods 0.000 claims description 16
- 238000002944 PCR assay Methods 0.000 claims description 13
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 12
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims description 12
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 12
- 238000005096 rolling process Methods 0.000 claims description 9
- 238000009825 accumulation Methods 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- -1 SCCA1.2 Proteins 0.000 claims description 7
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 5
- 238000011901 isothermal amplification Methods 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 238000003491 array Methods 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 101150084967 EPCAM gene Proteins 0.000 claims 26
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 26
- 101150057140 TACSTD1 gene Proteins 0.000 claims 26
- 101000922002 Conus purpurascens Conotoxin p5a Proteins 0.000 claims 24
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 claims 24
- 101001133631 Lysinibacillus sphaericus Penicillin acylase Proteins 0.000 claims 24
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 20
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 20
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 20
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 16
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 claims 12
- 101000994460 Homo sapiens Keratin, type I cytoskeletal 20 Proteins 0.000 claims 10
- 101000975502 Homo sapiens Keratin, type II cytoskeletal 7 Proteins 0.000 claims 8
- 102100031672 Homeobox protein CDX-1 Human genes 0.000 claims 7
- 101000777808 Homo sapiens Homeobox protein CDX-1 Proteins 0.000 claims 7
- 201000009030 Carcinoma Diseases 0.000 claims 4
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 101150042775 tyr1 gene Proteins 0.000 claims 1
- 239000013615 primer Substances 0.000 description 112
- 238000006243 chemical reaction Methods 0.000 description 99
- 238000003752 polymerase chain reaction Methods 0.000 description 86
- 241000894007 species Species 0.000 description 60
- 102100034343 Integrase Human genes 0.000 description 49
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 48
- 108091093088 Amplicon Proteins 0.000 description 44
- 239000002299 complementary DNA Substances 0.000 description 31
- 230000008569 process Effects 0.000 description 24
- 238000000137 annealing Methods 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 108010066302 Keratin-19 Proteins 0.000 description 18
- 239000002987 primer (paints) Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 15
- 102000054384 Villin-1 Human genes 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 210000005005 sentinel lymph node Anatomy 0.000 description 14
- 238000012216 screening Methods 0.000 description 13
- 108010066370 Keratin-20 Proteins 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 101710163270 Nuclease Proteins 0.000 description 10
- 230000003211 malignant effect Effects 0.000 description 10
- 108010070507 Keratin-7 Proteins 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 102000003425 Tyrosinase Human genes 0.000 description 9
- 108060008724 Tyrosinase Proteins 0.000 description 9
- 238000011002 quantification Methods 0.000 description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 7
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 6
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000007403 mPCR Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 102100036383 Serpin B3 Human genes 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 3
- 239000012807 PCR reagent Substances 0.000 description 3
- 102100030326 Serpin B4 Human genes 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 2
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 2
- 101001005722 Homo sapiens Melanoma-associated antigen 6 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 2
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 2
- 102100025075 Melanoma-associated antigen 6 Human genes 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 238000001921 nucleic acid quantification Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710190849 Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 101100043112 Homo sapiens SERPINB3 gene Proteins 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101150071808 PTHLH gene Proteins 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011549 displacement method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004190 ion pair chromatography Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58659904P | 2004-07-09 | 2004-07-09 | |
| US58701904P | 2004-07-09 | 2004-07-09 | |
| PCT/US2005/024194 WO2006017151A2 (en) | 2004-07-09 | 2005-07-08 | Identification of makers in esophageal cancer, colon cancer, head and neck cancer and melanoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011190962A Division JP2012005500A (ja) | 2004-07-09 | 2011-09-01 | 食道癌、結腸癌、頭頸部癌、およびメラノーマにおけるマーカーの同定 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008505644A true JP2008505644A (ja) | 2008-02-28 |
| JP2008505644A5 JP2008505644A5 (enExample) | 2008-08-21 |
Family
ID=35839738
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007520520A Pending JP2008505644A (ja) | 2004-07-09 | 2005-07-08 | 食道癌、結腸癌、頭頸部癌、およびメラノーマにおけるマーカーの同定 |
| JP2007520519A Pending JP2008510454A (ja) | 2004-07-09 | 2005-07-08 | 肺癌および乳癌におけるマーカーの同定 |
| JP2011190962A Withdrawn JP2012005500A (ja) | 2004-07-09 | 2011-09-01 | 食道癌、結腸癌、頭頸部癌、およびメラノーマにおけるマーカーの同定 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007520519A Pending JP2008510454A (ja) | 2004-07-09 | 2005-07-08 | 肺癌および乳癌におけるマーカーの同定 |
| JP2011190962A Withdrawn JP2012005500A (ja) | 2004-07-09 | 2011-09-01 | 食道癌、結腸癌、頭頸部癌、およびメラノーマにおけるマーカーの同定 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US7662561B2 (enExample) |
| EP (6) | EP1774025A4 (enExample) |
| JP (3) | JP2008505644A (enExample) |
| AU (2) | AU2005271960B2 (enExample) |
| CA (2) | CA2571642A1 (enExample) |
| WO (2) | WO2006017150A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011078223A1 (ja) * | 2009-12-24 | 2011-06-30 | 国立大学法人愛媛大学 | 頸部リンパ節転移分析方法及び頭頸部癌の腫瘍マーカー |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050112622A1 (en) | 2003-08-11 | 2005-05-26 | Ring Brian Z. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| US20060003391A1 (en) * | 2003-08-11 | 2006-01-05 | Ring Brian Z | Reagents and methods for use in cancer diagnosis, classification and therapy |
| EP1774025A4 (en) * | 2004-07-09 | 2009-09-16 | Univ Pittsburgh | IDENTIFYING MARKERS IN LUNG AND BREAST CANCER |
| US20080131916A1 (en) * | 2004-08-10 | 2008-06-05 | Ring Brian Z | Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy |
| JP2008515393A (ja) * | 2004-09-20 | 2008-05-15 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 複数モードの多重化反応消去方法 |
| JP4968577B2 (ja) * | 2006-04-11 | 2012-07-04 | エフ.ホフマン−ラ ロシュ アーゲー | サイトケラチン19(CK19)mRNAの迅速測定法、並びにそのためのプライマー及びプローブ |
| US8119352B2 (en) * | 2006-06-20 | 2012-02-21 | Cepheld | Multi-stage amplification reactions by control of sequence replication times |
| JP4943074B2 (ja) * | 2006-07-03 | 2012-05-30 | シスメックス株式会社 | がん転移の判定方法及び装置 |
| US7622456B2 (en) * | 2006-11-06 | 2009-11-24 | Non-Profit Organization Chang Gung Memorial Hospital | Method on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degree of cancer, serving as a molecular target and using RNA jamming sequence on inhibition-specific of DSG3 expression |
| CA2669600A1 (en) * | 2006-11-13 | 2008-05-29 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for identification, monitoring, and treatment of lung cancer |
| US9151762B2 (en) | 2009-06-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Identification of DSG-3 as a biomarker for the detection of metastasis in lymph nodes |
| EP2516429B1 (en) | 2009-12-22 | 2020-06-24 | Avon Products, Inc. | Paxillin stimulating compositions and cosmetic uses thereof |
| EP2659004B1 (en) | 2010-12-30 | 2017-08-30 | Avon Products, Inc. | Modulation of dynein in skin |
| US9771617B2 (en) | 2011-06-27 | 2017-09-26 | Eisai R&D Management Co., Ltd. | Microrna biomarkers indicative of alzheimer's disease |
| US10195136B2 (en) | 2011-08-24 | 2019-02-05 | Avon Products, Inc. | Collagen and elastin stimulating compositions and uses thereof |
| US8709507B2 (en) | 2011-12-13 | 2014-04-29 | Avon Products, Inc. | Maesa japonica extracts and methods of use |
| US8632827B2 (en) | 2011-12-13 | 2014-01-21 | Avon Products, Inc | Modulation of thymosin beta-4 in skin |
| JP2013208420A (ja) * | 2012-03-02 | 2013-10-10 | Nippon Koden Corp | 心電図解析レポート、心電図解析装置及び心電図解析プログラム |
| JP6419694B2 (ja) * | 2012-06-29 | 2018-11-07 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | 横方向挿入脊椎インプラント |
| CN108949992B (zh) * | 2018-08-14 | 2021-11-05 | 高鑫 | 一种与食管鳞癌及其分级相关的生物标志物 |
| CN109913552B (zh) * | 2019-03-27 | 2020-08-04 | 河北医科大学第四医院 | 一种食管鳞癌诊疗靶点及应用 |
| EP4116435A1 (en) * | 2021-07-08 | 2023-01-11 | Universidad de Granada | In vitro method for the diagnosis and/or prognosis of malignant melanoma |
| WO2023081988A1 (pt) * | 2021-11-09 | 2023-05-19 | Coelho Guilherme Portela | Método para predição de eficácia de tratamento para câncer de mama |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274087A (en) | 1986-08-13 | 1993-12-28 | Molecular Diagnostics, Inc. | cDNA coding for carcinoembryonic antigen (CEA) |
| US6379895B1 (en) * | 1989-06-07 | 2002-04-30 | Affymetrix, Inc. | Photolithographic and other means for manufacturing arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6406844B1 (en) * | 1989-06-07 | 2002-06-18 | Affymetrix, Inc. | Very large scale immobilized polymer synthesis |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US6346413B1 (en) | 1989-06-07 | 2002-02-12 | Affymetrix, Inc. | Polymer arrays |
| ES2091976T3 (es) * | 1991-06-20 | 1996-11-16 | Hoffmann La Roche | Metodos perfeccionados para la amplificacion del acido nucleico. |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| EP0732929B1 (en) | 1993-10-29 | 2008-05-14 | The Brigham And Women's Hospital, Inc. | Therapeutic use of cis-element decoys in vivo |
| US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| AU5310296A (en) | 1995-03-17 | 1996-10-08 | John Wayne Cancer Institute | Detection of melanoma or breast metastases with a multiple marker assay |
| JP4484967B2 (ja) | 1995-06-06 | 2010-06-16 | ベス イスラエル ディーコネス メディカル センター | Dna診断試験の方法及び装置 |
| US5882856A (en) | 1995-06-07 | 1999-03-16 | Genzyme Corporation | Universal primer sequence for multiplex DNA amplification |
| US6031129A (en) * | 1995-10-03 | 2000-02-29 | Quantum Chemical Corporation | Use of pentavalent group VA oxides in acetic acid processing |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5837442A (en) * | 1995-11-29 | 1998-11-17 | Roche Molecular Systems, Inc. | Oligonucleotide primers for amplifying HCV nucleic acid |
| AUPO188396A0 (en) | 1996-08-26 | 1996-09-19 | Insearch Limited | Detection of protozoan parasites |
| US5958349A (en) | 1997-02-28 | 1999-09-28 | Cepheid | Reaction vessel for heat-exchanging chemical processes |
| US5843721A (en) | 1997-07-03 | 1998-12-01 | Tularik Inc. | Nucleic acids encoding human NIK protein |
| GB9719044D0 (en) | 1997-09-08 | 1997-11-12 | Inst Of Ophthalmology | Assay |
| EP1179585B1 (en) | 1997-12-24 | 2008-07-09 | Cepheid | Device and method for lysis |
| US6660228B1 (en) | 1998-03-02 | 2003-12-09 | Cepheid | Apparatus for performing heat-exchanging, chemical reactions |
| US6037129A (en) * | 1998-05-28 | 2000-03-14 | Medical University Of South Carolina | Multi-marker RT-PCR panel for detecting metastatic breast cancer |
| US6306643B1 (en) | 1998-08-24 | 2001-10-23 | Affymetrix, Inc. | Methods of using an array of pooled probes in genetic analysis |
| US6245517B1 (en) | 1998-09-29 | 2001-06-12 | The United States Of America As Represented By The Department Of Health And Human Services | Ratio-based decisions and the quantitative analysis of cDNA micro-array images |
| US6431476B1 (en) | 1999-12-21 | 2002-08-13 | Cepheid | Apparatus and method for rapid ultrasonic disruption of cells or viruses |
| EP1146869A2 (en) | 1999-01-27 | 2001-10-24 | University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
| US6251601B1 (en) | 1999-02-02 | 2001-06-26 | Vysis, Inc. | Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarrays |
| US6300069B1 (en) | 1999-05-03 | 2001-10-09 | Qiagen Gmbh | Generation and amplification of nucleic acids from ribonucleic acids |
| EP1208189B1 (en) | 1999-05-28 | 2004-10-06 | Cepheid | Device and method for analysing liquid samples |
| ATE333938T1 (de) | 1999-05-28 | 2006-08-15 | Cepheid | Patrone zum durchführen einer chemischen reaktion |
| SE9902410D0 (sv) | 1999-06-24 | 1999-06-24 | Cavidi Tech Ab | Reverse transcriptase assay kit, use thereof and method for analysis of RT activity in biological samples |
| AU5830400A (en) * | 1999-06-30 | 2001-01-22 | Arto Orpana | Diagnostic method for squamous cell carcinoma |
| US6403037B1 (en) | 2000-02-04 | 2002-06-11 | Cepheid | Reaction vessel and temperature control system |
| US6844153B2 (en) * | 2000-03-27 | 2005-01-18 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| US6783934B1 (en) | 2000-05-01 | 2004-08-31 | Cepheid, Inc. | Methods for quantitative analysis of nucleic acid amplification reaction |
| US20020168647A1 (en) * | 2000-08-03 | 2002-11-14 | Tongtong Wang | Compositions and methods for the therapy and diagnosis of head and neck cancer |
| US6374684B1 (en) | 2000-08-25 | 2002-04-23 | Cepheid | Fluid control and processing system |
| US8048386B2 (en) | 2002-02-25 | 2011-11-01 | Cepheid | Fluid processing and control |
| WO2002037113A2 (en) * | 2000-11-03 | 2002-05-10 | Michael Giesing | Clinical and functional validation of targets from disseminated cancer cells |
| US6312929B1 (en) | 2000-12-22 | 2001-11-06 | Cepheid | Compositions and methods enabling a totally internally controlled amplification reaction |
| CA2439402A1 (en) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pcr method |
| EP1464695A1 (en) | 2001-12-26 | 2004-10-06 | Olympus Corporation | Reaction vessel and reaction vessel holding mechanism |
| US6819027B2 (en) | 2002-03-04 | 2004-11-16 | Cepheid | Method and apparatus for controlling ultrasonic transducer |
| EP2261368A1 (en) * | 2002-03-13 | 2010-12-15 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| CN1659287A (zh) * | 2002-04-05 | 2005-08-24 | 美国政府健康及人类服务部 | 诊断肝癌转移或发病可能性及鉴定治疗靶点的方法 |
| EP1540002A2 (en) * | 2002-09-12 | 2005-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for detection of micro-metastasis |
| US7910295B2 (en) * | 2002-11-14 | 2011-03-22 | John Wayne Cancer Institute | Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimarker quantitative RT-PCR |
| US20040101859A1 (en) | 2002-11-25 | 2004-05-27 | Cepheid | Compositions, methods and kits for polynucleotide amplification reactions and microfluidic devices |
| WO2005055804A2 (en) * | 2003-12-02 | 2005-06-23 | Musc Foundation For Research Development | Methods and compositions for diagnosing epithelial cell cancer |
| EP1774025A4 (en) * | 2004-07-09 | 2009-09-16 | Univ Pittsburgh | IDENTIFYING MARKERS IN LUNG AND BREAST CANCER |
| JP2008515393A (ja) * | 2004-09-20 | 2008-05-15 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 複数モードの多重化反応消去方法 |
| US9032602B2 (en) | 2011-07-15 | 2015-05-19 | The Boeing Company | Methods and systems for in-process quality control during drill-fill assembly |
-
2005
- 2005-07-08 EP EP05764654A patent/EP1774025A4/en not_active Ceased
- 2005-07-08 CA CA002571642A patent/CA2571642A1/en not_active Abandoned
- 2005-07-08 EP EP10183722A patent/EP2287329A3/en not_active Withdrawn
- 2005-07-08 WO PCT/US2005/024193 patent/WO2006017150A2/en not_active Ceased
- 2005-07-08 AU AU2005271960A patent/AU2005271960B2/en not_active Ceased
- 2005-07-08 JP JP2007520520A patent/JP2008505644A/ja active Pending
- 2005-07-08 EP EP05770149A patent/EP1774030A4/en not_active Withdrawn
- 2005-07-08 EP EP10183644A patent/EP2272987A3/en not_active Withdrawn
- 2005-07-08 JP JP2007520519A patent/JP2008510454A/ja active Pending
- 2005-07-08 US US11/178,134 patent/US7662561B2/en not_active Expired - Fee Related
- 2005-07-08 EP EP12151990A patent/EP2468889A3/en not_active Withdrawn
- 2005-07-08 US US11/178,109 patent/US20060068418A1/en not_active Abandoned
- 2005-07-08 WO PCT/US2005/024194 patent/WO2006017151A2/en not_active Ceased
- 2005-07-08 EP EP10183750A patent/EP2275578A3/en not_active Withdrawn
- 2005-07-08 CA CA002571650A patent/CA2571650A1/en not_active Abandoned
- 2005-07-08 AU AU2005271961A patent/AU2005271961B8/en not_active Ceased
-
2009
- 2009-12-15 US US12/637,862 patent/US20100240037A1/en not_active Abandoned
-
2011
- 2011-02-17 US US13/030,003 patent/US20110312515A1/en not_active Abandoned
- 2011-09-01 JP JP2011190962A patent/JP2012005500A/ja not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011078223A1 (ja) * | 2009-12-24 | 2011-06-30 | 国立大学法人愛媛大学 | 頸部リンパ節転移分析方法及び頭頸部癌の腫瘍マーカー |
| US8715931B2 (en) | 2009-12-24 | 2014-05-06 | National University Corporation Ehime University | Method for analyzing cervical lymph node metastasis, and tumor marker for head and neck cancer |
| JP5807877B2 (ja) * | 2009-12-24 | 2015-11-10 | 国立大学法人愛媛大学 | 頸部リンパ節転移分析方法及び頭頸部癌の腫瘍マーカー |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005271961B8 (en) | 2011-11-24 |
| CA2571642A1 (en) | 2006-02-16 |
| EP2287329A2 (en) | 2011-02-23 |
| JP2012005500A (ja) | 2012-01-12 |
| EP1774030A2 (en) | 2007-04-18 |
| US20060068418A1 (en) | 2006-03-30 |
| AU2005271960A1 (en) | 2006-02-16 |
| US20060019290A1 (en) | 2006-01-26 |
| EP1774025A4 (en) | 2009-09-16 |
| US7662561B2 (en) | 2010-02-16 |
| EP2272987A2 (en) | 2011-01-12 |
| AU2005271960B2 (en) | 2011-12-08 |
| WO2006017151A3 (en) | 2007-01-11 |
| WO2006017150A2 (en) | 2006-02-16 |
| EP1774025A2 (en) | 2007-04-18 |
| EP2272987A3 (en) | 2012-04-11 |
| EP2468889A3 (en) | 2012-07-11 |
| CA2571650A1 (en) | 2006-02-16 |
| US20100240037A1 (en) | 2010-09-23 |
| EP2275578A2 (en) | 2011-01-19 |
| EP2275578A3 (en) | 2011-11-30 |
| AU2005271961B2 (en) | 2011-10-13 |
| EP2468889A2 (en) | 2012-06-27 |
| AU2005271961A1 (en) | 2006-02-16 |
| EP2287329A3 (en) | 2011-08-03 |
| EP1774030A4 (en) | 2008-07-09 |
| US20110312515A1 (en) | 2011-12-22 |
| WO2006017150A3 (en) | 2009-04-09 |
| JP2008510454A (ja) | 2008-04-10 |
| WO2006017151A2 (en) | 2006-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012005500A (ja) | 食道癌、結腸癌、頭頸部癌、およびメラノーマにおけるマーカーの同定 | |
| EP1272668B1 (en) | Methods, compositions and kits for the detection and monitoring of breast cancer | |
| US20230366034A1 (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
| US7767390B2 (en) | Methods for evaluating drug-resistance gene expression in the cancer patient | |
| JP2008515393A (ja) | 複数モードの多重化反応消去方法 | |
| CN107858434B (zh) | lncRNA在肝癌诊断以及预后预测中的应用 | |
| AU2005250479B2 (en) | Diagnosing or predicting the course of breast cancer | |
| WO2011104694A2 (en) | Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes | |
| CN101236193A (zh) | 胃癌的淋巴结转移的检测 | |
| CN112813168B (zh) | 一种与口腔鳞癌相关的生物标志物 | |
| WO2023145754A1 (ja) | 膀胱癌の存在を検出するためのプライマー及びプローブ | |
| WO2024204599A1 (ja) | 膀胱癌のバイオマーカー | |
| WO2024204603A1 (ja) | 膀胱癌のバイオマーカー | |
| AU2011253566A8 (en) | Identification of markers in esophageal cancer, colon cancer, head and neck cancer and melanoma | |
| BRPI1006640A2 (pt) | métodos e reagentes para a detecção precoce de melanoma | |
| HK1130514A (en) | Diagnosing or predicting the course of breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080707 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080707 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110301 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110530 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110901 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110907 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120222 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120508 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120515 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121031 |